Company Overview
Gilead Sciences delivered impressive Q1 2026 earnings on April 24th—five days ago—reporting revenue of $7.3 billion (up 7% year-over-year) and earnings per share of $2.14 that crushed analyst expectations of $1.92. The biopharmaceutical company demonstrated strength across its product portfolio, with HIV franchise revenue of $4.9 billion (up 5%) stabilizing after years of generic competition concerns, while its oncology division grew 15% driven by Trodelvy and cell therapy sales.
What makes Gilead particularly compelling right now is the lenacapavir momentum revealed during the April 24th earnings call. CEO Daniel O’Day highlighted that lenacapavir—Gilead’s revolutionary twice-yearly injectable HIV prevention and treatment medication—is on track for FDA approval for prevention (PrEP) in Q3 2026 after Phase 3 trials showed 99.9% efficacy in preventing HIV transmission. This represents a paradigm shift from daily pills to a twice-yearly injection, potentially expanding the prevention market to millions who struggle with daily medication adherence.
Key Technical and Fundamental Drivers
Strong Q1 Beat → April 24th Results
Gilead reported Q1 2026 results five days ago showing $7.3B revenue (up 7% YoY), $2.14 EPS (crushing $1.92 estimates), with HIV franchise stabilizing and oncology accelerating.
Lenacapavir Breakthrough → 99.9% HIV Prevention
Twice-yearly injectable lenacapavir showed 99.9% efficacy in preventing HIV transmission in Phase 3 trials, with FDA PrEP approval expected Q3 2026 unlocking $5+ billion market.
HIV Franchise Stabilization → $4.9B Quarterly
HIV business generated $4.9 billion in Q1 (up 5%), with Biktarvy maintaining dominance and lenacapavir adding growth as next-generation long-acting option.
Oncology Growth → 15% Acceleration
Oncology division grew 15% year-over-year driven by Trodelvy (breast cancer, bladder cancer) and Yescarta (CAR-T cell therapy) gaining market share.
Cash Generation → $8B+ Annual Free Cash Flow
Gilead generates over $8 billion in annual free cash flow with minimal debt, enabling aggressive share buybacks ($3B in 2025) and a 4% dividend yield.
Market Takeaway
Gilead’s April 24th earnings—five days ago—demonstrate a biotech company successfully navigating the patent cliff transition while building next-generation growth drivers. The lenacapavir approval expected in Q3 2026 represents one of the most significant HIV prevention advances in decades, with the potential to dramatically expand the market beyond the current 1-2 million people taking daily PrEP pills.
The twice-yearly injectable addressing HIV prevention’s biggest challenge: adherence. Studies show 40-50% of people prescribed daily PrEP pills fail to take them consistently, leaving them vulnerable to infection. A medication requiring only two injections per year (administered at clinics) essentially eliminates adherence issues. The 99.9% efficacy demonstrated in Phase 3 trials is extraordinary—essentially preventing all HIV transmission when used as prescribed. This positions lenacapavir to become the standard of care for PrEP once approved.
The market opportunity is massive and underappreciated. Currently, only 30-40% of the 1.2 million Americans who could benefit from PrEP actually use it, primarily due to daily pill burden and stigma around picking up HIV medications monthly. Lenacapavir’s twice-yearly dosing could expand utilization to 70-80% of eligible populations, while also opening markets in developing countries where daily medication access is challenging. Analysts project lenacapavir could reach $5-7 billion in annual peak sales across prevention and treatment indications.
The HIV franchise stabilization is equally important—Biktarvy revenue remaining strong at $3+ billion quarterly demonstrates Gilead’s continued dominance in HIV treatment despite generic competition for older drugs. The company has successfully transitioned patients to newer, patent-protected regimens, extending the franchise’s growth runway. The oncology business growing 15% provides diversification beyond HIV, with Trodelvy approved for multiple cancer indications (breast, bladder, lung) that could drive the drug to $3+ billion in peak sales. Yescarta CAR-T cell therapy competing with Novartis and BMS in blood cancers adds another billion-dollar asset.
Gilead’s massive free cash flow ($8+ billion annually) relative to its $85 billion market cap creates exceptional shareholder return potential. The company generates roughly 10% free cash flow yield, allowing it to return substantial capital through dividends (4% yield) and buybacks ($3 billion in 2025) while maintaining fortress balance sheet with minimal debt. Trading at depressed valuations around 10-12x forward earnings—a significant discount to biotech peers despite revenue growth and pipeline catalysts—Gilead offers contrarian value with substantial upside if lenacapavir lives up to its blockbuster potential. The Q3 2026 FDA decision provides a clear near-term catalyst that could drive significant rerating as investors recognize the franchise transformation from mature HIV business to next-generation growth story.